{"title":"Steric Hindrance-Engineered Redox-Responsive Disulfide-Bridged Homodimeric Prodrug Nanoassemblies for Spatiotemporally Balanced Cancer Chemotherapy.","authors":"Tian Liu,Fengli Xia,Yi Zheng,Hongying Xiao,Yuanhao Yu,Jianbin Shi,Shuo Wang,Xianbao Shi,Zhonggui He,Jin Sun,Bingjun Sun","doi":"10.1021/acs.jmedchem.5c00810","DOIUrl":null,"url":null,"abstract":"The rational design of tumor-responsive prodrug nanoassemblies requires precise control over systemic stability and site-specific activation. While α-position disulfide bonds are advantageous for rapid response to redox conditions, they also risk premature drug leakage during circulation. This study introduces a steric hindrance-guided approach to engineer disulfide-bridged podophyllotoxin homodimeric prodrugs for spatiotemporal controlled delivery. By monomethyl or dimethyl substitution of the carbon atoms adjacent to the α-disulfide bond, we can modulate steric hindrance. Excessive hindrance destabilizes the nanoassemblies and slows effective drug release, while moderate hindrance (monomethyl modification) enhances pharmacokinetic properties and promotes selective tumor activation. In vivo studies indicate that monomethyl-modified prodrug nanoassemblies exhibit superior antitumor efficacy and reduced off-target toxicity compared to PPT solution. This work underscores the importance of steric hindrance in optimizing prodrug nanoassembly stability and tumor-specific activation, offering a comprehensive strategy for redox-responsive nanomedicines.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"1 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00810","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The rational design of tumor-responsive prodrug nanoassemblies requires precise control over systemic stability and site-specific activation. While α-position disulfide bonds are advantageous for rapid response to redox conditions, they also risk premature drug leakage during circulation. This study introduces a steric hindrance-guided approach to engineer disulfide-bridged podophyllotoxin homodimeric prodrugs for spatiotemporal controlled delivery. By monomethyl or dimethyl substitution of the carbon atoms adjacent to the α-disulfide bond, we can modulate steric hindrance. Excessive hindrance destabilizes the nanoassemblies and slows effective drug release, while moderate hindrance (monomethyl modification) enhances pharmacokinetic properties and promotes selective tumor activation. In vivo studies indicate that monomethyl-modified prodrug nanoassemblies exhibit superior antitumor efficacy and reduced off-target toxicity compared to PPT solution. This work underscores the importance of steric hindrance in optimizing prodrug nanoassembly stability and tumor-specific activation, offering a comprehensive strategy for redox-responsive nanomedicines.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.